Latest From Omeros Corp.
The latest drug development news and highlights from our US FDA Performance Tracker.
A Phase III trial design change could result in quicker patient access for Calliditas’s product candidate for Berger’s disease, and boost the growth potential for the Swedish biotech.
The pipeline for new drug candidates remains healthy as 2019 begins, with almost 40 novel agents already under FDA review. But the chances of another record-breaking year are threatened by a confluence of safety issues that are putting risk management back in the spotlight – and by the widening ripple effects of the recent US government shutdown.
In tandem with Roivant, Cincinnati Children’s launches spinout Aruvant focused on hematologic disorders and separately teams with BridgeBio on genetic disease therapies. Roivant spinout Axovant licenses gene therapy candidates from University of Massachusetts.
- Large Molecule
- Site Specific
- Generic Drugs
- Drug Delivery
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Neurology, Nervous System
- Renal System
- North America
- Parent & Subsidiaries
- Omeros Corp.
- Senior Management
Gregory A Demopulos, MD, Chmn. & CEO
Timothy M Duffy, PhD, VP, Bus. Dev.
George A Gaitanaris, MD, PhD, CSO
Eckard Leifke, MD, VP, Clin. Dev. & CMO
- Contact Info
Phone: (206) 676-5000
201 Elliott Ave. W.
Seattle, WA 98119
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.